2025
Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
Grady C, Bhattacharjee B, Silva J, Jaycox J, Lee L, Silva Monteiro V, Sawano M, Massey D, Caraballo C, Gehlhausen J, Tabachnikova A, Mao T, Lucas C, Peña-Hernandez M, Xu L, Tzeng T, Takahashi T, Herrin J, Güthe D, Akrami A, Assaf G, Davis H, Harris K, McCorkell L, Schulz W, Griffin D, Wei H, Ring A, Guan L, Dela Cruz C, Krumholz H, Iwasaki A. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. Communications Medicine 2025, 5: 163. PMID: 40346201, PMCID: PMC12064684, DOI: 10.1038/s43856-025-00829-3.Peer-Reviewed Original ResearchSpike protein-specific IgGProtein-specific IgGSelf-antigensImmune response to COVID-19 vaccinationCOVID-19 vaccineAntibody responseResponse to COVID-19 vaccinationT cell expansionSARS-CoV-2-specific antibody responsesAssociated with no improvementLong COVIDAssociated with symptom improvementChest painCirculating cytokinesImmune phenotypeProspective studyImmune featuresTransient improvementPrimary seriesVaccine doseHerpes virusImmune responseSymptom improvementSignificant elevationImpact of COVID-19 vaccinationLILRB3 genetic variation is associated with kidney transplant failure in African American recipients
Sun Z, Yi Z, Wei C, Wang W, Ren T, Cravedi P, Tedla F, Ward S, Azeloglu E, Schrider D, Li Y, Khan A, Zanoni F, Fu J, Ali S, Liu S, Liang D, Liu T, Li H, Xi C, Vy T, Mosoyan G, Sun Q, Kumar A, Zhang Z, Farouk S, Campell K, Ochando J, Lee K, Coca S, Xiang J, Connolly P, Gallon L, O’Connell P, Colvin R, Menon M, Nadkarni G, He J, Kraft M, Jiang X, Zhang X, Kiryluk K, Cherukuri A, Lakkis F, Zhang W, Chen S, Heeger P, Zhang W. LILRB3 genetic variation is associated with kidney transplant failure in African American recipients. Nature Medicine 2025, 1-11. PMID: 40065170, DOI: 10.1038/s41591-025-03568-z.Peer-Reviewed Original ResearchSingle-nucelotide polymorphismsAssociated with death-censored graft lossDeath-censored graft lossGenetic variationGraft lossImmunoreceptor tyrosine-based inhibitory motifTyrosine-based inhibitory motifAA individualsApolipoprotein L1Rate of graft lossEnd-stage renal diseaseMissense mutationsInhibitory motifRNA sequencingKidney transplant outcomesKidney transplant failureMultiomics analysisImmune-related diseasesAmino acidsAfrican American recipientsTransplant cohortTransplant failureTransplant outcomesAnalysis of bloodProspective studyProspective REALITI-A Study 2-Year Real-World Benefits of Mepolizumab in Severe Asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A Study 2-Year Real-World Benefits of Mepolizumab in Severe Asthma. CHEST Pulmonary 2025, 3: 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reductionA Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trials127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients
Chan N, Gaule P, Benanto J, Robbins C, Scott L, Hill S, Morrison R, Liebler D, Fulton R, Rimm D. 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients. Laboratory Investigation 2025, 105: 102351. DOI: 10.1016/j.labinv.2024.102351.Peer-Reviewed Original ResearchEfficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease
Chen H, Colasurdo M, Khunte M, Malhotra A, Gandhi D. Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease. Neurology 2025, 104: e210243. PMID: 39772663, DOI: 10.1212/wnl.0000000000210243.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeTreated with IV thrombolysisIn-hospital mortalityMoyamoya disease patientsIV thrombolysisMoyamoya diseasePropensity score matchingIntracranial hemorrhageRisk factors of acute ischemic strokeSelf-careIschemic stroke patientsAcute ischemic stroke patientsStroke patientsTreating acute ischemic strokeNationwide Readmissions DatabaseRisk factorsRate of routine dischargeRoutine dischargeEfficacy outcomesAssociated with different ratesProspective studyBypass surgeryRetrospective analysisEstablished treatmentReadmissions Database
2024
Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis
Sassano M, Seyyedsalehi M, Kappil E, Zhang S, Zheng T, Boffetta P. Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis. Environmental Research 2024, 266: 120606. PMID: 39672496, DOI: 10.1016/j.envres.2024.120606.Peer-Reviewed Original ResearchPooled relative riskRelative riskHead and neckEstimate pooled relative risksConfidence intervalsExposure to per-Evidence of publication biasNatural log-unit increaseThyroid cancerCase-control studyPolyfluoroalkyl substances exposuresAssociated with lungPublication biasSystematic reviewPositive associationMeasured serum levelsMeta-analysisSerum PFAS levelsTesticular cancerProspective studyAssociationSerum levelsPFAS exposureExposure assessmentLung cancerClonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort
Jaber Chehayeb R, Singh J, Matute-Martinez C, Chen N, Guajardo A, Lin D, Jayakrishnan R, Christofides A, Leveille E, Im Y, Biancon G, VanOudenhove J, Ibrahim E, Ardasheva A, Jha A, Hwa J, Halene S, Kwan J. Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort. Cardio-Oncology 2024, 10: 84. PMID: 39587635, PMCID: PMC11590368, DOI: 10.1186/s40959-024-00289-z.Peer-Reviewed Original ResearchImmune checkpoint inhibitor myocarditisImmune checkpoint inhibitorsImmune checkpoint inhibitor useICI-myocarditisIndeterminate potentialProspective studyImmune checkpoint inhibitor therapyCancer therapyClonal hematopoiesis of indeterminate potentialCancer treated with immunotherapyIncreased T cell activationObstructive coronary artery diseaseMultivariate competing risk analysisCardiotoxic cancer therapyRisks Cox regressionAssociated with increased riskIncreased all-cause mortalityPatient co-morbiditiesRisk of cardiomyopathyT cell activationCompeting risk analysisCoronary artery calcificationCoronary artery diseaseAll-cause mortalityHeart failure patientsIncorporation of the central vein sign into the McDonald criteria
Amin M, Nakamura K, Daboul L, O'Donnell C, Cao Q, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prčkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Incorporation of the central vein sign into the McDonald criteria. Multiple Sclerosis And Related Disorders 2024, 93: 106182. PMID: 39622133, PMCID: PMC11779579, DOI: 10.1016/j.msard.2024.106182.Peer-Reviewed Original ResearchCentral vein signDIS criteriaDiagnostic performanceMultiple sclerosisDeep white matter lesionsDiagnosis of multiple sclerosisMulti-center studyInternational multi-center studyWhite matter lesionsNorth American ImagingMcDonald CriteriaProspective studyDiagnostic accuracyMRI disseminationDemyelinating diseaseBackground DiagnosisMS diagnosisDiagnostic biomarkersCompare sensitivityLesionsBrain locationsMethods DataBrain imagingBrainSignsMachine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators
Rosman L, Lampert R, Wang K, Gehi A, Dziura J, Salmoirago-Blotcher E, Brandt C, Sears S, Burg M. Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators. Journal Of The American College Of Cardiology 2024, 85: 42-55. PMID: 39570241, DOI: 10.1016/j.jacc.2024.09.006.Peer-Reviewed Original ResearchImplantable cardioverter-defibrillatorYear of device implantationAll-cause mortalityCardiac resynchronization therapyDeath/HF hospitalizationValidation cohortHeart failureDevice implantationTime of ICD implantationArea under the receiver-operating characteristic curveMedian follow-upReceiver-operating characteristic curvePredicting all-cause mortalityImplantable cardioverter-defibrillator patientsVeterans Health AdministrationPersonalized risk estimatesImplantable cardioverter defibrillatorResynchronization therapyBaseline demographicsICD implantationTraining cohortTrajectories of individual patientsProspective studyComposite outcomeContinuum of riskPlasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at 18F-SynVesT-1 Brain PET Imaging.
Wu J, Li B, Wang J, Huang Q, Chen X, You Z, He K, Guo Q, Li S, Huang Y, Guo T, Dai W, Xiang W, Chen W, Yang D, Zhao J, Guan Y, Xie F. Plasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at 18F-SynVesT-1 Brain PET Imaging. Radiology 2024, 313: e233019. PMID: 39560478, PMCID: PMC11605102, DOI: 10.1148/radiol.233019.Peer-Reviewed Original ResearchConceptsP-tau-181Alzheimer's diseaseAD-related pathologyAmyloid-bPhosphor-tauTau pathologySynaptic densityTau accumulationSynaptic lossTauTau-PETDecreased synaptic densityGlial fibrillary acidic proteinPlasma glial fibrillary acidic proteinCortical thicknessAcidic proteinFibrillary acidic proteinRuijin HospitalProspective studyRelationship of plasmaBlood assayBlood markersPET/MRIBrain PET imagingPET imagingEffect of Indoor Residual Spraying on Malaria in Pregnancy and Pregnancy Outcomes: A Systematic Review
Oberlin A, Kim T, Erlinger A, Joshi A, Diawara H, Healy S, Dicko A, Duffy P, Hacker M, Wylie B. Effect of Indoor Residual Spraying on Malaria in Pregnancy and Pregnancy Outcomes: A Systematic Review. American Journal Of Tropical Medicine And Hygiene 2024, 112: 253-265. PMID: 39471507, PMCID: PMC11803663, DOI: 10.4269/ajtmh.24-0435.Peer-Reviewed Original ResearchIndoor residual sprayingEffectiveness of indoor residual sprayingPreterm birthBirth outcomesIncreased risk of preterm birthIncidence of malaria parasitemiaRisk of preterm birthResidual sprayingMalaria-endemic areasUrogenital birth defectsFetal/neonatal mortalityMaternal malariaPlacental malariaMalaria parasitemiaObstetric outcomesPerinatal morbidityFetal anomaliesPregnancy outcomesPerinatal mortalityLow birthweightProspective studyPregnancyBirth defectsIncreased riskMalariaEffect of endoscopic ultrasound guided celiac plexus block on the palliation of pain in chronic pancreatitis (EPOCH Trial): study protocol for a randomized multicenter sham-controlled trial {1}
Wilcox C, Bang J, Buxbaum J, Gardner T, Hawes R, Kedia P, Mardini S, Muniraj T, Navaneethan U, Oza V, Tarnasky P, Thakkar S, Waxman I, Varadarajulu S. Effect of endoscopic ultrasound guided celiac plexus block on the palliation of pain in chronic pancreatitis (EPOCH Trial): study protocol for a randomized multicenter sham-controlled trial {1}. Trials 2024, 25: 676. PMID: 39396987, PMCID: PMC11472533, DOI: 10.1186/s13063-024-08478-y.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAutonomic Nerve BlockCeliac PlexusEndosonographyHumansMulticenter Studies as TopicNerve BlockPain MeasurementPalliative CarePancreatitis, ChronicProspective StudiesRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUltrasonography, InterventionalUnited StatesConceptsCeliac plexus blockAbdominal painChronic pancreatitisVisual analog scalePlexus blockSham-controlled trialRandomized sham-controlled trialEndoscopic ultrasound-guided celiac plexus blockEffectiveness of endoscopic ultrasoundBrief Pain Inventory Short FormDocumented chronic pancreatitisPainful chronic pancreatitisPalliation of painTime of EUSTreatment of abdominal painPain scoresBPI-SFSteroid combinationsAnalog scaleEndoscopic ultrasoundProspective studyCeliac plexusRandomized trialsShort formPancreatitisComprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation: A prospective cohort study.
Hughes T, Treffalls R, Koek W, Dalton H, Karam O, Meyer A. Comprehensive secondary analysis of thrombotic events in pediatric patients receiving extracorporeal membrane oxygenation: A prospective cohort study. Perfusion 2024, 2676591241289358. PMID: 39352407, DOI: 10.1177/02676591241289358.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenationMultiple thrombotic eventsThrombotic eventsMembrane oxygenationPediatric extracorporeal membrane oxygenationMulti-center prospective studyEvaluate predictive factorsDays of therapyPlatelet transfusion volumeProspective cohort studyTransfusion volumeBinomial regressionPediatric patientsProlonged ECMOPlatelet volumePredictive factorsProspective studyUnivariate analysisAnti-XaCohort studySeverity scoreHigh riskPatientsAntithrombin IIIScoring toolCardiac Disease in Pregnancy
Cifuentes J, Fardelmann K. Cardiac Disease in Pregnancy. 2024, 41-53. DOI: 10.1007/978-3-031-62756-9_6.Peer-Reviewed Original ResearchCongenital heart diseaseCardiac diseaseHeart diseasePregnant patientsPrevalence of congenital heart diseaseMaternal-fetal medicine physiciansRegistry of pregnanciesHigh-risk pregnanciesPregnancy-related mortalityProportion of patientsIncreasing maternal ageValvular heart diseasePeripartum planFetal outcomesMaternal morbidityPostpartum managementAntepartum periodDelivery hospitalizationsChronic medical conditionsComplication rateMaternal ageProspective studyDiabetes mellitusCardiothoracic surgeonsPregnancyThe Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives
Gringeri E, Furlanetto A, Billato I, Cescon M, De Carlis L, Mazzaferro V, Romagnoli R, De Simone P, Vivarelli M, Di Benedetto F, Ravaioli M, Lauterio A, Sposito C, Patrono D, Ghinolfi D, Moccheggiani F, Di Sandro S, D’Amico F, Lanari J, Gambato M, Trapani S, Bergamo F, Cardillo M, Burra P, Cillo U. The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives. Updates In Surgery 2024, 76: 2505-2513. PMID: 39210194, DOI: 10.1007/s13304-024-01889-1.Peer-Reviewed Original ResearchNeoadjuvant radio-chemotherapyPerihilar cholangiocarcinomaLiver transplantationGroup 1Radio-chemotherapyGroup 2Standard of care chemotherapyRisk of cancer-related deathInclusion criteriaPeri-hilar cholangiocarcinomaRecurrence-free survivalResults of LTRisk regression analysisCancer-related deathsLiver transplant centersMayo protocolNeoadjuvant regimenNeoadjuvant treatmentCare chemotherapyOverall survivalProspective studyMayo ClinicHazard ratioTransplant centersIneffective treatmentAssociation between childhood abuse and risk of post-COVID-19 conditions: Results from three large prospective cohort studies
Vyas C, Wang S, Menor A, Kubzansky L, Slopen N, Rich-Edwards J, Chavarro J, Kang J, Roberts A. Association between childhood abuse and risk of post-COVID-19 conditions: Results from three large prospective cohort studies. Brain Behavior And Immunity 2024, 123: 143-150. PMID: 39191351, PMCID: PMC11698154, DOI: 10.1016/j.bbi.2024.08.046.Peer-Reviewed Original ResearchPost-COVID-19 conditionPost-COVID conditionsHealth-relatedPhysical/emotional abusePsychological factorsRisk of poor health outcomesGrowing Up Today StudyNurses' Health StudyPoor health outcomesAssociated with riskAssociated with increased riskChildhood abusePost-COVID-19COVID-19 surveyCOVID-19 questionnaireHealth outcomesHealth StudyProspective studyEmotional abuse subscaleSexual abuseSelf-reportCohort studyNo childhood abuseCOVID-19-related symptomsToday StudyEvaluation and Management of Biliary Dyskinesia in Children and Adolescents: A Systematic Review From the APSA Outcomes and Evidence-Based Committee
Kulaylat A, Lucas D, Chang H, Derderian S, Beres A, Ham P, Huerta C, Sulkowski J, Wakeman D, Englum B, Gulack B, Acker S, Gonzalez K, Levene T, Christison-Lagay E, Mansfield S, Yousef Y, Pennell C, Russell K, Rentea R, Tashiro J, Diesen D, Alemayehu H, Ricca R, Kelley-Quon L, Rialon K. Evaluation and Management of Biliary Dyskinesia in Children and Adolescents: A Systematic Review From the APSA Outcomes and Evidence-Based Committee. Journal Of Pediatric Surgery 2024, 59: 161678. PMID: 39227244, DOI: 10.1016/j.jpedsurg.2024.08.018.Peer-Reviewed Original ResearchSystematic reviewBiliary dyskinesiaOxford Levels of EvidencePreferred Reporting ItemsGrading of RecommendationsAmerican Pediatric Surgical Association OutcomesRisk of biasEvidence-based recommendationsDiagnostic criteriaPredictors of symptom reliefLevel of evidenceNon-operative managementResolution of symptomsPediatric-specific guidelinesOutcome of medical managementLong-term outcomesReporting ItemsNon-randomized studiesOxford LevelsMeta-analysesMethodological IndexAssociated outcomesClinical entityProspective studySymptom reliefHereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network
DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.Peer-Reviewed Original ResearchConceptsHereditary antithrombin deficiencyLow-molecular-weight heparinVenous thromboembolismOral anticoagulantsAT concentrateAdverse eventsIncreased risk of venous thromboembolismRisk factorsRisk of venous thromboembolismDirect oral anticoagulantsAmerican ThrombosisSeventy-nine patientsDeep vein thrombosisHemostasis NetworkRecurrent thrombosisConcentrate administrationPulmonary embolismAntithrombin deficiencyThrombotic eventsVein thrombosisProspective studyPredominant manifestationArterial thrombosisGlobal RegistryIncreased riskReal‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem 2024, 5: 728-737. PMID: 39157611, PMCID: PMC11327707, DOI: 10.1002/jha2.981.Peer-Reviewed Original ResearchPatients treated with ICEvent-free survivalTreated with ICCore binding factor acute myeloid leukemiaGemtuzumab ozogamicinIntensive chemotherapyCBF-AMLAcute myeloid leukemiaKIT inhibitorsOverall survivalEuropean LeukemiaNetMyeloid leukemiaThree-year overall survivalMedian follow-upInduction treatment regimensAntibody-drug conjugatesStatistically significant differenceImproved OSFavorable riskSurvival benefitTreatment regimensProspective studyFollow-upCompare outcomesAcademic centers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply